Home / Resources / Videos / ADA 2017 / Jim McDermott Part 2, Efficacy Of SGLT2 Inhibitors

Jim McDermott Part 2, Efficacy Of SGLT2 Inhibitors

In part 2 of this Exclusive Interview, Dr. Jim McDermott explains what research shows about the the efficacy of SGLT2 inhibitors and their benefit to risk ratio in a conversation with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA.

Jim McDermott, PhD, is the Vice President of U.S. Medical Affairs, Diabetes at AstraZeneca.


Transcript of this video segment:

Freed: I don’t know if you remember the troglitazone drug? It was pulled off the market for liver failure. To this day I am not sure if it was the drug. I think it was found that the doctors were not providing the right liver test to find out which patients would be suitable. But that put a scare in to the medical community as far as writing prescriptions for new drugs. So what would you tell the PCP to make him feel more comfortable with this drug because it’s only been available for a couple of years?

McDermott: Right. I think I would show them the efficacy, because I think it’s a story, right? What’s the benefit-risk of the product? So you want to talk about the efficacy. And again, I mentioned the great A1C reduction, blood pressure reduction, weight loss, and then you also need to tell them about some of the common side effects seen across class such as genital infections, urinary tract infections, and slight risk of hypotension. I think it’s really about educating physicians on the benefit-risk and it’s not just SGLT-2. it’s across the treatment portfolio that they have an opportunity to use.

Freed: Well you are presenting a lot of information. Obviously you are presenting information on Bydureon, a GLP-1. What kind of information are you presenting on that particular as far as the efficacy and side effects?

McDermott: Yeah so we had a great study that we are presenting and we’re very proud of – it’s called DURATION-8 and it’s actually a combination of Bydureon and Farxiga together as initial combination therapy. Since we do have Farxiga, an SGLT-2, and Bydureon, a GLP-1; we’ve gotten a lot of questions from physicians about the possibility of using those in combination and at that time we really didn’t have a lot of data. So what we did is a randomized control trial looking at the combination vs. the individual components. Here at ADA, it’s really exciting because we’re showing a 1-year results and what you’re seeing is sustainability out to a year. So you’re having that A1C reduction, very significant with the combination, great blood pressure reduction and weight loss, and all three of those are sustained over a 1-year period.

Return to the main page.